Emergent BioSolutions Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Emergent BioSolutions Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Emergent BioSolutions Inc. - Product Pipeline Review - 2014', provides an overview of the Emergent BioSolutions Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Emergent BioSolutions Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Emergent BioSolutions Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Emergent BioSolutions Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Emergent BioSolutions Inc.'s pipeline products

Reasons to buy

- Evaluate Emergent BioSolutions Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Emergent BioSolutions Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Emergent BioSolutions Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Emergent BioSolutions Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Emergent BioSolutions Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Emergent BioSolutions Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Emergent BioSolutions Inc. Snapshot 6
Emergent BioSolutions Inc. Overview 6
Key Information 6
Key Facts 6
Emergent BioSolutions Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Emergent BioSolutions Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Emergent BioSolutions Inc. - Pipeline Products Glance 14
Emergent BioSolutions Inc. - Late Stage Pipeline Products 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Emergent BioSolutions Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Emergent BioSolutions Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Emergent BioSolutions Inc. - Drug Profiles 20
trenonacog alfa 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NP-015 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AV-7909 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
otlertuzumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PreviThrax 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AVP-21D9 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Anti-CD19 X Anti-CD3 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Anti-H5HA mAB 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Anti-HER2 X Anti-CD3 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Anti-RON X Anti-CD3 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CTLA-4 X mono-IL-10 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ES-210 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ES-301 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ES-306 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ES-414 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IB1-008 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MVA-H5HA 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MVA-RSV 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Recombinant Botulinum Vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TNFR x A2 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TNFR x TWEAKR 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Emergent BioSolutions Inc. - Pipeline Analysis 43
Emergent BioSolutions Inc. - Pipeline Products by Target 43
Emergent BioSolutions Inc. - Pipeline Products by Route of Administration 45
Emergent BioSolutions Inc. - Pipeline Products by Molecule Type 46
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action 47
Emergent BioSolutions Inc. - Recent Pipeline Updates 49
Emergent BioSolutions Inc. - Dormant Projects 59
Emergent BioSolutions Inc. - Discontinued Pipeline Products 61
Discontinued Pipeline Product Profiles 61
Immune Globulin 61
Leucotropin 61
PEP-35 61
TST-10088 61
Emergent BioSolutions Inc. - Company Statement 62
Emergent BioSolutions Inc. - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Emergent BioSolutions Inc., Key Information 6
Emergent BioSolutions Inc., Key Facts 6
Emergent BioSolutions Inc. - Pipeline by Indication, 2014 8
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2014 10
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2014 11
Emergent BioSolutions Inc. - Partnered Products in Pipeline, 2014 12
Emergent BioSolutions Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13
Emergent BioSolutions Inc. - Filing rejected/Withdrawn, 2014 14
Emergent BioSolutions Inc. - Phase III, 2014 15
Emergent BioSolutions Inc. - Phase II, 2014 16
Emergent BioSolutions Inc. - Phase I, 2014 17
Emergent BioSolutions Inc. - Preclinical, 2014 18
Emergent BioSolutions Inc. - Pipeline by Target, 2014 44
Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2014 45
Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2014 46
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action, 2014 48
Emergent BioSolutions Inc. - Recent Pipeline Updates, 2014 49
Emergent BioSolutions Inc. - Dormant Developmental Projects,2014 59
Emergent BioSolutions Inc. - Discontinued Pipeline Products, 2014 61
Emergent BioSolutions Inc., Other Locations 64
Emergent BioSolutions Inc., Subsidiaries 65